Switching biologics in children with psoriasis: Results from the BiPe cohort

Abstract

Background: There is currently little information on switching biologics in pediatric psoriasis.Objective: To evaluate the real-world clinical practice and safety of switching biologics in the "Biological Treatments for Pediatric Psoriasis" (BiPe) cohort. Methods: Data for all 134 patients included in the BiPe cohort were analyzed. A further evaluation of the subpopulation of patients who switched from a first-line Pediatric Dermatology PHAN et Al.

Effectiveness and Safety of Adalimumab, Etanercept and Ustekinumab for Severe Psoriasis in Children Under 12 Years of Age: A French-Italian Daily Practice Cohort (BiPe Jr)

“…In our study, 19.4% of the children switched biological agents at least once, a level close to that observed in the BiPe cohort (22%) [26]. The majority of switches between biological agents involved only etanercept or adalimumab, and nearly all children treated with ustekinumab did not require switching to another biological treatment.…”

Biologics combined with conventional systemic agents for the treatment of children with severe psoriasis. Real‐life data from the BiPe cohorts and a practice survey among French and Italian pediatric dermatologists

“…For example, issues related to switching between biologics (i.e., safety, efficacy and loss of efficacy in secondline settings) have only been evaluated recently, with the results showing that there were no significant differences in drug survival between the three major switches evaluated (adalimumab to ustekinumab, etanercept to adalimumab, and etanercept to ustekinumab), and no new safety alerts. 15 Other issues, such as the optimization of systemic treatments in children and the use of combinations of systemic treatments, remain to be evaluated. These additional studies are needed to avoid the potential dangers associated with extrapolating adult recommendations to children.…”

“…However, the studies conducted so far have not answered all of the questions surrounding the use of these treatments in the daily practice management of children with psoriasis, and some patients may still have unmet needs. For example, issues related to switching between biologics (i.e., safety, efficacy and loss of efficacy in second‐line settings) have only been evaluated recently, with the results showing that there were no significant differences in drug survival between the three major switches evaluated (adalimumab to ustekinumab, etanercept to adalimumab, and etanercept to ustekinumab), and no new safety alerts 15 . Other issues, such as the optimization of systemic treatments in children and the use of combinations of systemic treatments, remain to be evaluated.…”

Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching

“…Due to the chronic nature of psoriasis [1][2][3], the affected patients may experience several comorbidities (i.e., respiratory [4][5][6][7][8], cardiovascular [9][10][11][12][13] or gastrointestinal ones [14][15][16][17]) and therapy failures [18][19][20][21][22][23][24][25]. Thus, therapeutic strategies play a pivotal in limiting the psoriasis detrimental progression and the quality of life worsening.…”